All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
LevFinLevFin Leveraged Loans

Merck spin-off launches first slug of $9.5bn debt-raising

Pharma_drugs_adobe_575x375.jpg

Organon, a spin-off of US pharmaceuticals company Merck, has launched the first $3bn of a $9.5bn capital raising that will give the soon-to-be independent group its own debt capital structure and fund a one-off special dividend to its parent.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree